|
DNAJC25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.68354219454159E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.7196244428419E-12 |
| Normal-vs-Stage2 |
2.029900E-04 |
| Normal-vs-Stage3 |
3.46559447805816E-11 |
| Normal-vs-Stage4 |
1.6251444634463E-12 |
| Stage1-vs-Stage2 |
2.845000E-01 |
| Stage1-vs-Stage3 |
2.328400E-01 |
| Stage1-vs-Stage4 |
4.163400E-04 |
| Stage2-vs-Stage3 |
9.905500E-02 |
| Stage2-vs-Stage4 |
1.235450E-03 |
| Stage3-vs-Stage4 |
5.141900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.44089209850063E-16 |
| Normal-vs-AfricanAmerican |
1.377150E-03 |
| Normal-vs-Asian |
3.55460105794236E-12 |
| Caucasian-vs-AfricanAmerican |
3.813400E-01 |
| Caucasian-vs-Asian |
9.761800E-01 |
| AfricanAmerican-vs-Asian |
3.981000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.79329884275603E-11 |
| Normal-vs-Female |
8.59312621059871E-14 |
| Male-vs-Female |
9.853600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.77635683940025E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11277653758179E-12 |
| Normal-vs-Age(61-80Yrs) |
2.10520001431291E-09 |
| Normal-vs-Age(81-100Yrs) |
1.369660E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.438200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.252400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.449600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.691000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.494600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.614000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.62189999711282E-08 |
| Classical-VS-Follicular |
1.158380E-04 |
| Classical-VS-Other |
8.279000E-01 |
| Classical-VS-Normal |
1.64235292032799E-12 |
| Tall-VS-Follicular |
3.79296594132938E-12 |
| Tall-VS-Other |
1.520840E-03 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
7.093700E-02 |
| Follicular-VS-Normal |
9.021600E-03 |
| Other-VS-Normal |
1.782550E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.11410000616752E-09 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
3.83390000000539E-05 |
|
|
